1. Home
  2. ABLV vs CELU Comparison

ABLV vs CELU Comparison

Compare ABLV & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABLV

Able View Global Inc.

HOLD

Current Price

$0.75

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.00

Market Cap

35.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABLV
CELU
Founded
2015
2016
Country
China
United States
Employees
89
123
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.5M
35.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ABLV
CELU
Price
$0.75
$1.00
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
398.2K
24.3K
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$76.00
P/E Ratio
$16.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$1.01
52 Week High
$1.77
$4.35

Technical Indicators

Market Signals
Indicator
ABLV
CELU
Relative Strength Index (RSI) 51.71 25.14
Support Level $0.60 N/A
Resistance Level $0.93 $1.46
Average True Range (ATR) 0.09 0.08
MACD 0.01 -0.03
Stochastic Oscillator 42.74 3.55

Price Performance

Historical Comparison
ABLV
CELU

About ABLV Able View Global Inc.

Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: